
Eli Lilly and Company company profile
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.37T
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products within a single business segment. Its portfolio includes insulin analogs for diabetes, incretin-based medicines for type 2 diabetes and obesity, and oncology, immunology, and dermatology treatments. The company manufactures and distributes its products through facilities in the United States, including Puerto Rico, Europe, and Asia, and sells them in approximately 90 countries. Its customers include wholesale distributors, pharmacies, pharmacy benefit managers, insurers, hospitals, and government institutions. In the U.S., most products are distributed through wholesalers, and three of them each accounted for a significant share of consolidated revenue. The company also sells directly to patients through LillyDirect, a digital platform.
A summary of the business section of the company's latest annual report, filed 12 Feb 2026.
Company facts
| Ticker | LLY · NYSE |
|---|
| Sector | Pharmaceuticals |
|---|
| Industry | Pharmaceuticals |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 59478 |
|---|
| Latest annual report | 10-K, filed 12 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| David Ricks | President, Chair, and CEO · Director | 816K · < 1% | Gift, 3 Nov 2026 |
|---|
| Daniel Skovronsky, M.D., Ph.D. | EVP, CS&PO & Pres. LRL | 236K · < 1% | Gift, 2 Nov 2026 |
|---|
| Anat Hakim | EVP, GC & Secretary | 55.6K · < 1% | Sale under a 10b5-1 plan, 2 Nov 2026 |
|---|
| Lucas Montarce | EVP & CFO | 16.3K · < 1% | Option exercise, 1 Nov 2026 |
|---|
| J. Erik Fyrwald | Director | 1.7K · < 1% | Grant or award, 19 Oct 2026 |
|---|
| Ralph Alvarez | Director | 758 · < 1% | Grant or award, 19 Oct 2026 |
|---|
| Mary Lynne Hedley | Director | 346 · < 1% | Grant or award, 15 Dec 2025 |
|---|
| Jamere Jackson | Director | 200 · < 1% | Grant or award, 17 Nov 2025 |
|---|
| Gabrielle Sulzberger | Director | 117 · < 1% | Grant or award, 19 Oct 2026 |
|---|
| Juan Luciano | Director | 0 · < 1% | Grant or award, 19 Oct 2026 |
|---|
| Katherine Baicker, Ph.D. | Director | 0 · < 1% | Grant or award, 17 Nov 2025 |
|---|
| Kimberly Johnson | Director | 0 · < 1% | Grant or award, 17 Nov 2025 |
|---|
| William Kaelin, Jr., M.D. | Director | 0 · < 1% | Grant or award, 17 Nov 2025 |
|---|
| Jonsson Patrik | EVP & President, LLY Int'l | — | Gift, 10 Nov 2026 |
|---|
| Brown Adrienne S | EVP, President LLY Imm | — | Option exercise, 1 Nov 2026 |
|---|
| Custer Kenneth L. | EVP & President, Card Met Hlth | — | Option exercise, 1 Nov 2026 |
|---|
| Dozier Eric | EVP, Chief People Officer | — | Option exercise, 1 Nov 2026 |
|---|
| Hernandez Edgardo | EVP & Pres., Mfg. Operations | — | Option exercise, 1 Nov 2026 |
|---|
| Seymour Melissa | EVP, Global Quality | — | Gift, 9 Sep 2026 |
|---|
| Zakrowski Donald A | SVP, Finance, & CAO | — | Sale under a 10b5-1 plan, 10 Aug 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
LLY in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.